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Herbal medicine (HM) as an adjunct therapy has been shown to be promising for the chronic obstructive pulmonary disease
(COPD). However, the role of herbs in COPD remains largely unexplored. In this present study, we conducted the systematic
review to evaluate the efficacy of herbs in COPD. 176 clinical studies with reporting pulmonary function were retrieved from
English and Chinese database. Commonly used herbs for acute exacerbations stage (AECOPD) and stable COPD stage (SCOPD)
were identified. Ameta-analysis conducted from 15 high quality studies (18 publications) showed thatHMas an adjunct therapy had
no significant improvement in pulmonary function (FEV
1
, FEV%, FVC, and FEV
1
/FVC) compared to conventional medicine.The
efficacy of the adjunct HM on improving the arterial blood gas (PaCO
2
and PaO
2
) for AECOPD and SCOPD remains inconclusive
due to the heterogeneity among the studies. However, HM as an adjunct therapy improved clinical symptoms and quality of life
(total score, activity score, and impact score of St. George’s Respiratory Questionnaire). Studies with large-scale and double-blind
randomized controlled trials are required to confirm the role of the adjunct HM in the management of COPD.
1. Introduction
Chronic obstructive pulmonary disease (COPD) is a progres-
sive and chronic lung disease. It is the fourth leading cause of
death as reported by the World Health Organization. COPD
is characterized by chronic cough, excess sputumproduction,
chest tightness, and shortness of breath during physical activ-
ity [1]. In the EuropeanUnion, the total direct costs of respira-
tory diseases are estimated to be about 6% of the total health
care budget, withCOPDaccounting for 56%of the cost under
respiratory diseases [2]. Studies have predicted that the rank
of disability adjusted life years (DALYs) in COPD will rise
from the seventh to fifth by 2030 [3, 4]. Though stable COPD
(SCOPD) and acute exacerbations (AECOPD) are treatable
[5–9], there is no cure. Studies have shown the promising
herbal medicine (HM) (including Chinese medicine and
medicinal plant or its derivatives from other countries) in
relieving COPD by attenuating disease symptoms, improving
quality of life and pulmonary function [10–13], and reducing
the frequency, duration, and severity of exacerbations [14].
Emerging studies also demonstrated the anti-inflammatory
and antioxidative effect of HM in COPD disease [10, 15–17].
Recently, several systematic reviews have been conducted,
indicating the potential effectiveness of Chinese herbal
medicine in COPD [18–25]. However, the efficacy remains
inconclusive due to low quality of studies. Pulmonary func-
tion has been considered the gold standard to the diagnosis of
COPD. In the present study, we systematically reviewed the
efficacy of HM on COPD using the pulmonary function as
the primary outcome. In addition, the commonly used herbs
and secondary outcome such as quality of life and clinical
symptoms were analyzed.
2. Methods
2.1. Search Strategy. Search strategy used in this study was as
follows: (ChinesemedicineORTraditional ChineseMedicine
OR Chinese herbal medicine OR Chinese herbal drug OR
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traditional herbal medicine OR herbal medicine OR tra-
ditional Japanese medicine OR traditional medicine OR
Ethnomedicine OR Folk Medicine OR Folk Remedies OR
Home Remedies OR Indigenous Medicine OR Primitive
Medicine OR Materia Medica OR Homeopathic Reme-
dies OR Nosodes OR traditional East Asian medicine OR
Traditional Far Eastern Medicine OR Far East Medicine
OR Oriental medicine OR Korean medicine OR Tibetan
medicine OR herb OR herbaceous agent OR medicinal plant
OR medicinal herbs OR medicinal plant product OR plant
extract OR plant preparation OR Herbal Preparation OR
botanic OR botany OR Kampo OR Kampo medicine OR
Kanpo OR Traditional Mongolian Medicine OR Mongolian
FolkMedicineORMongolianMedicineORphytotherapyOR
Herb Therapy OR Herbal Therapy OR Ethnopharmacology
OR Ethnobotany OR phytogenics OR alternative medicine
OR Alternative Therapy OR complementary therapy OR
Complementary Medicine OR TCM OR CHM OR Zhong
Yi Xue) AND (Chronic obstructive pulmonary disease OR
COPD OR chronic obstructive lung disease OR chronic
obstructive airway disease OR chronic airflow limitation OR
chronic obstructive respiratory diseaseORchronic bronchitis
OR chronic emphysema OR shortness of breath OR SOB OR
dyspnea).The keywords search was conducted inMarch 2012
and updated in November 2013.
2.2. Database. Search strategy followed the Cochrane Col-
laboration without restriction of the language for publica-
tions. The following databases were searched: (1) PubMed;
(2) MEDLINE; (3) EMBASE; (4) Cochrane Central Register
of Controlled Trials (CENTRAL); (5) Cochrane Database of
Systematic Reviews; (6) AMED; (7) China Academic Journal
Full Text Database; and (8) China Master and Doctor Theses
Full-Text Database.
2.3. Inclusion Criteria. Inclusion criteria included all pub-
lished studies reporting quasi or randomized controlled trials
(RCTs) and comparing HM or its variants as monotherapy or
adjuvant therapy, with at least one control group that used
the conventional western practice or placebo. Participants
were required to have had a diagnosis of COPD according to
the investigators of the trials. There would be no restriction
on the ethnicity, gender, age, or disease duration of the
participants in the trials. The HM interventions could have
been either (1) extract(s) from a single herb; (2) prepara-
tion(s) containing multiple herbs; or (3) proprietary herbal
product(s). They should be used alone or coadministered
with western medications. The control intervention has to
be either a placebo or a western medication (WM). Trials
of all durations are welcomed. Both parallel and crossover
designs would be accepted. Clinical studies had to report the
pulmonary function in the research.
2.4. Exclusion Criteria. Studies without baseline and end-
point of pulmonary function tests during clinical trials were
excluded.
2.5. Data Synthesis. All analyses were performed with Rev-
Man version 5.1 (TheNordic Cochrane Centre,TheCochrane
Collaboration) to quantify and compare the efficacy of out-
comes of the treatment versus the control groups. Standard
mean difference was given for continuous outcome variable
with 95% confidence interval (CI), while odds ratio (OR)
was given for dichotomous outcome variable with 95% CI.
The random-effect model was employed when the study
of heterogeneity (I2) was larger than 50%; otherwise a fix-
effect model was used when the I2 was less than 50%.
To test the heterogeneity, subgroup analysis was performed
according to the AECOPD and SCOPD. The 𝑍 test was used
to compare the overall effects of the treatment groups and the
control groups; differences were considered to be statistically
significant when 𝑃 < 0.05.
3. Results
3.1. Characterization of Studies Included. 7286 publications
and theses were screened by the abstracts and retrieved
from databases by two individual reviewers (HC and CM).
6702 publications were excluded while 584 full articles
were further assessed for eligibility. 408 publications were
excluded due to the lack of data in pulmonary function
and randomization in clinical trials. 176 of the studies that
satisfied the criteria were included for further analysis. Risk
bias of these studies was assessed by seven features including
the sequence generation, allocation concealment, blinding of
participants and personnel, blinding of outcome assessment,
incomplete outcome data, selective outcome reporting, and
other biases. Studieswith four ormore features judged to have
low risk bias were regarded as high quality studies. Eighteen
high quality publications were identified according to the
risk bias assessment tool (Figure 1). Four studies reported
the same clinical trial. Therefore, fifteen studies were meta-
analyzed for the pulmonary function, symptoms assessment,
and quality of life assessment. The characteristics of 15 high
quality studies were shown in Table 1. Flow chart of the
included studies was shown in Figure 2.
3.2. Commonly Used Herbal Medicines in COPD. To iden-
tify the commonly used HMs in COPD, we counted the
frequency of herb medicines utilized in the 176 clinical
trials (Table S1; see Supplementary Material available online
at http://dx.doi.org/10.1155/2014/925069). Commonly used
HMs for AECOPD and SCOPD were identified as shown
in Figure 3. Among commonly used herb medicines, eight
herbs including Fructus Perillae (Zi Su Zi), Pericarpium
Citri Reticulatae (Chen Pi), Poria (Fu Ling), Radix Astragali
(Huang Qi), Radix Glycyrrhizae (Gan Cao), Radix Salviae
Miltiorrhizae (Dan Shen), Rhizoma Pinelliae (Ban Xia), and
Semen Armeniacae Amarum (Xin Ren) were always used for
both AECOPD and SCOPD. To further confirm the findings,
fourteen commonly used herbal medicines were identified
in the clinical studies without indicating acute exacerbation
or stable stage in COPD (mixed COPD). Interestingly, the
aforementioned eight most frequently used HMs emerged
again. In addition, six other HMs including Herba Ephedrae
(MaHuang), Radix Scutellariae (HuangQin), SemenPersicae
(Tao Ren), Fructus Schisandrae (WuWei Zi), Radix Ginseng
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Figure 1: Risk of bias. Risk of bias for the included studies was
assessed according to the information that comes from studies at
low, unclear, or high risk of bias for each item in the risk of bias tool.
(Ren Shen), and Rhizoma Atractylodis Macrocephalae (Bai
Zhu) used in studies were also found commonly prescribed
in AECOPD and SCOPD. Specifically, Herba Ephedrae (Ma
Huang), Radix Scutellariae (HuangQin), and Semen Persicae
(Tao Ren) were among the highly frequently used herbs for
AECOPD studies, whereas Fructus Schisandrae (WuWei Zi),
Radix Ginseng (Ren Shen), and Rhizoma Atractylodis Mac-
rocephalae (Bai Zhu) were identified as the highly frequently
used herbs for SCOPD.
3.3. Pulmonary Function. Next, we conducted meta-analysis
for the included 15 studies [11, 14, 23, 26–40]. Nine studies [14,
26, 27, 29, 31, 34–37] reported the forced expiratory volume in
1 second (FEV
1
) and showed that HM as an adjunct therapy
had no advantage on improving FEV
1
compared to WM
(overall effect: 𝑃 = 0.18, heterogeneity: I2 = 0%, Figure 4(a)),
whereas the baseline of two groups had no significant differ-
ence (overall effect: 𝑃 = 1.00, heterogeneity: I2 = 0%, Table
S2). Eleven high quality studies [26–31, 33, 34, 37, 39, 40]
reported FEV% and showed that HM as an adjunct therapy
had no advantage on improving FEV% compared with WM
Records identified through
database searching
(n = 7286)
Records screened
(n = 7286)
Records excluded
(n = 6702)
Full-text articles assessed for
eligibility (n = 584)
Full text articles excluded due
to lack of pulmonary function
and randomization in clinical
trials (n = 408)
Studies included in qualitative
synthesis (n = 18)
Studies included in
quantitative synthesis
(meta-analysis) (n = 15)
Four publications reported the
same clinical trial. The four
publications are regard as one
study
Studies excluded due to less 
than 4 of 7 items in low risk bias 
(risk bias assessment tool) 
Risk bias assessed for
Eligibility (n = 176)
(n = 158)
Figure 2: Flow diagram on the screening of study. Fifteen of the
studies with high quality were meta-analyzed.
(overall effect: 𝑃 = 0.10, heterogeneity: I2 = 32%) as shown
in Figure 4(b), whereas the baseline of two groups had no
significant difference in FEV% (overall effect: 𝑃 = 0.26,
heterogeneity: I2 = 0%, Table S2). Seven studies [14, 27, 29,
31, 34, 35, 37] reported the forced vital capacity (FVC); pooled
data showed that HM as an adjunct therapy had no advantage
on improving FVC compared toWM(overall effect:𝑃 = 0.35,
heterogeneity: I2 = 0%, Figure 4(c)), whereas the baseline
of two groups had no significant difference in FVC (overall
effect: 𝑃 = 0.42, heterogeneity: I2 = 0%) as shown in Table S2.
Finally, analysis of FEV
1
/FVC in six high quality studies
[27–30, 33, 37] consistently showed that HM as an adjunct
therapy had no advantage of improving FEV
1
/FVC compared
to WM (overall effect: 𝑃 = 0.23; heterogeneity: I2 = 83%).
The heterogeneity is due to the discrepancy of Li study [30].
After dropping the latter study, the result was in line with
the previous finding that HM as an adjunct therapy had
no advantage compared to WM (overall effect: 𝑃 = 0.57;
heterogeneity: 𝑃 = 0.90) shown in Figure 4(d).
3.4. Arterial Blood Gas. Five high quality studies [26, 29, 34,
36, 39] reported the blood gas data. Analysis of blood gas
showed that HM as an adjunct therapy had an advantage
on reducing PaCO
2
and increasing PaO
2
. However, there
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Figure 3: Commonly used herbal medicines from the frequency analysis. The eight Chinese medicines were overlapped in AECOPD and
SCOPD, which were further confirmed in the mixed COPD studies.
was significant heterogeneity among the studies. Subgroup
analysis also indicated the efficacy of the adjunct HM for
SCOPD, and AECOPD remains inconclusive due to the
heterogeneity of studies (Figure S1).
3.5. Symptoms Assessment. Studies reported symptom imp-
rovement according to SFDAGuidelines onClinical Research
of TCMNewDrugs [41].The improvement (≥30%) of clinical
symptoms and Chinese medicine symptoms was regarded
as effective treatment outcome. The pooled analysis of 7
studies [27, 29, 30, 33, 34, 37, 38] showed that HM as an
adjunct therapy significantly improved the clinical symptoms
compared toWM (overall effect: 𝑃 < 0.00001, heterogeneity:
I2 = 0%) as shown in Figure 5(a).
3.6. Quality of Life Assessment. Five studies reported the find-
ings using St. George’s Respiratory Questionnaire (SGRQ),
including 3 SCOPD studies [27, 28, 38], 1 AECOPD study
[14], and 1 mixed COPD study [33]. As shown in Figure 5(b),
subgroup analysis showed that HM as an adjunct therapy
had advantage on improving the total score of SGRQ in
SCOPD patients compared to WM (overall effect: 𝑃 = 0.02,
heterogeneity: I2 = 0%). Of these high quality studies, three
studies [14, 27, 38] reported symptoms, activities, and impacts
scores of SGRQ. Further analysis showed that activity and
impact scores of SGRQ in the adjunct HM were superior
compared to WM (overall effect: 𝑃 = 0.001, heterogeneity:
I2 = 0%; overall effect: 𝑃 = 0.0003, heterogeneity: I2 = 0%,
resp.) (Figures 5(c) and 5(d)), while the efficacy of the adjunct
HM in symptom score remains to be further determined due
to heterogeneity in the studies (overall effect: 𝑃 = 0.23, het-
erogeneity: I2 = 82%). The baseline TS, activity, impact, and
symptom scores were comparable (overall effect: 𝑃 = 0.22,
heterogeneity: I2 = 0%; overall effect:𝑃 = 0.30, heterogeneity:
I2 = 0%; overall effect: 𝑃 = 0.35, heterogeneity: I2 = 0%;
overall effect: 𝑃 = 0.70, heterogeneity: I2 = 0%, resp.) as
shown in Table S2.
3.7. Subgroup Analysis in Classification of COPD, the Route
of HM Administration, and in Placebo/Nonplacebo Groups.
We examined the outcome measures with subgroup analysis
(AECOPD, SCOP, and Mixed COPD). All outcomes mea-
sured show no significant difference among the subgroups
except for the SGRQ total score (𝑃 = 0.02) and PaCO
2
(𝑃 < 0.00001) (Table S4). Therefore the SGRQ total score
and PaCO
2
were further analyzed with subgroup analysis.
Subgroup analysis for the total score of SGRQwas conducted
above (Figure 5(b)). We also found that subgroup analysis of
PaCO
2
measurements indicating the significant heterogene-
ity among the AECOPD (𝑃 = 0.002) and data was not pooled
in SCOPD studies as only one study reported PaCO
2
.The role
of the adjunct HM in improving PaCO
2
remains inclusive for
both SCOPD and AECOPD patients.
In the subgroup analysis with the HM administration
route, only one study administrated HM in the route of injec-
tion [39], while the left used oral administration. The out-
comes involved in the study were FEV%, PaCO
2
, and PO
2
.
In a sensitivity test with dropping the study, no significant
changes were found in the three outcomes (FEV%, PaCO
2
,
and PO
2
) (data was not shown).
We further conducted the subgroup analysis in placebo/
nonplacebo groups. All outcomes measurements showed no
significant difference except for the SGRQ symptom. Sub-
group analysis of SGRQ symptom showed the boarding sig-
nificant differences between placebo and nonplacebo group
(Table S4). Further analysis showed that the subgroup differ-
ence may be one of the causes leading to the heterogeneity
of studies in the meta-analysis of SGRQ symptoms. However,
the subgroup analysis also indicated that the efficacy of the
adjunct HM in SGRQ symptom score remains to be further
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Figure 4: Pulmonary function tests. (a) FEV
1
. (b) FEV%. (c) FVC. (d) FEV/FVC.The pulmonary function test analysis showed that HM had
no advantage on improving pulmonary function compared to WM.
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Figure 5: Efficacy and quality of life evaluation. (a) Efficacy of symptom improvement. (b) Subgroup analysis of total score of SGRQ. (c)
Activity score of SGRQ. (d) Impact score of SGRQ. Data analysis showed that HM improved the efficacy and quality of life compared toWM.
SGRQ, St. George’s Respiratory Questionnaire.
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determined. Therefore, subgroup analysis for all outcomes
based on placebo and nonplacebo groups did not alter the
results in the present study.
4. Discussion
COPD is one of the leading causes ofmorbidity andmortality
worldwide; its economic and social burdens are substantial
and increasing [42–44]. Several systematic reviews have
shown the therapeutic potential of herbalmedicine forCOPD
[18–24]. However, no systematic review was conducted using
the pulmonary function as the primary outcome.The present
study provided the updated information on the efficacy of
HM treatment for COPD using the pulmonary function as
the primary outcome measurement, also including arterial
blood gas, clinical symptoms, and SGRQ measurements.
Pulmonary function is the essential criteria for the
diagnosis of COPD according to GOLD [1]. We found that
pooled studies revealed that HM as an adjunct therapy
had no advantage on improving the pulmonary function
(FEV
1
, FEV%, FVC, and FEV
1
/FVC) in these high quality
studies. In contrast, many studies in low quality claimed the
improvement of pulmonary function after HM treatment.
Interestingly, the pooled arterial blood gas test showed an
improvement of PaO
2
and PaCO
2
in COPD patients, but it
remains inclusive due to the heterogeneity among studies.
In addition, lung function impairment in Stages I and II of
SCOPD patients is not the most significant concern. But we
did not exclude these patients in the meta-analysis due to
lack of data from publications. The discrepancies need to be
further clarified using a large scale, well-designed clinical trial
and using the pulmonary function as the primary outcome.
Quality of life has become an important outcomemeasure
in COPD patients since COPD is a long term disease without
cure. SGRQ was widely used for QoL assessment in COPD
patients within 3 categories (activity, symptoms, and impact).
Analysis of SGRQ from high quality studies showed that
HM as an adjunct therapy had an advantage over WM on
total score, activity score, and impact score. However, the
efficacy of HM as an adjunct therapy in improving the symp-
toms remains unclear due to the presence of heterogeneity.
Importantly, the efficacy assessment of clinical symptoms
and Chinese medicine symptoms partly covers symptoms
assessed in SGRQ.Therefore, HM as an adjunct therapy may
have advantage on improving quality of life and symptom
compared to WM.
In the study, eight HMs frequently used for COPD were
identified from 176 studies. The HMs fully follow the princi-
ples of Chinese medicine prescription for treating AECOPD
and SCOPD. Furthermore, we found that the identified Chi-
nese medicines have functions of regulating qi to reduce
phlegm (e.g., Pericarpium Citri Reticulatae (Chen Pi), Rhi-
zoma Pinelliae (Ban Xia), Semen Armeniacae Amarum (Xin
Ren), and Fructus Perillae (Zi Su Zi)) as well as tonifying
qi and promoting blood circulation (Radix Astragali (Huang
Qi), Radix Salviae Miltiorrhizae (Dan Shen)). Herba Ephe-
drae (Ma Huang), Semen Persicae (Tao Ren), and Radix Scu-
tellariae (Huang Qin) have functions such as clearing heat,
promoting blood circulation, and facilitating flow in the lung.
Radix Ginseng (Ren Shen), Rhizoma Atractylodis Macro-
cephalae (Bai Zhu), and Fructus Schisandrae (Wu Wei Zi)
have the functions of tonifying qi, strengthening spleen to
reduce phlegm, and arresting persistent cough. The com-
monly used herbs for AECOPD and SCOPD in the study
were also aligned with the common differentiated symptoms
in Chinese medicine for COPD (phlegm-heat in AECOPD
and spleen and kidney deficiency in SCOPD).
Moreover, the usage of these herbs was also in line with
the biological actions of herbs discovered by modern science.
COPD is characterized by a chronic inflammation in the
pulmonary tissue [45]. It has been shown that Semen Arme-
niacae Amarum (Xin Ren) reduced airway inflammation
and selectively inhibited the type 2 helper T cell responses
[46]. Amygdalin, the active compound from Semen Arme-
niacae Amarum (Xin Ren), has the high affinity for 𝛽2-
Adrenoceptor [47] and may act as an agonist to induce
bronchodilation inCOPDpatients. Similarly, Fructus Perillae
(Zi Su Zi) has been shown to be anti-inflammatory in airway
and to restore the Th1/Th2 imbalance in the immune system
[48]. Radix Astragali (Huang Qi) has immunologic benefits
by stimulatingmacrophage and natural killer cell activity and
inhibiting T-helper cell type 2 cytokines [49].
Pericarpium Citri Reticulatae (Chen Pi), Rhizoma Pinel-
liae (Ban Xia), Poria (Fu Ling), and Radix Glycyrrhizae
(Gan Cao) identified in the study are the components of a
famous Chinese medicine formula, namely, Er-Chen decoc-
tion, which functions as the removing phlegm in the principle
of Chinese medicine. In vitro study shows that the extract
of Pericarpium Citri Reticulatae (Chen Pi) has antioxidant
and antimicrobial activities [50]. Studies have shown that
both Rhizoma Pinelliae (Ban Xia) and Poria (Fu Ling) have
sedative effects [51, 52], which may improve the quality of
sleep in COPD patients. Moreover, Rhizoma Pinelliae (Ban
Xia) inhibits TNF-𝛼-induced NF-𝜅B activation [53], and
the extraction from Poria (Fu ling) has immunoregulatory
effect [54]. In addition, San’ao decoction, a famous Chinese
medicine formula composed of three herbs identified in
the study, Semen Armeniacae Amarum (Xin Ren), Radix
Glycyrrhizae (Gan Cao), and Herba Ephedrae (Ma Huang),
has shown anti-inflammation and hyperresponsiveness in
airway of a murine model [55].
Though the molecular mechanisms of howHM improves
QoL and clinical symptoms of COPD patients remain
largely unexplored, multiple effects on anti-inflammation,
immunoregulation, sedation, and bronchodilation may be
central roles of Chinese medicine prescriptions in the COPD
treatment. In addition, the quality control of HMs was not
clearly stated in the included studies. The reproducibility of
these medications to COPD remains to be further explored.
Analysis of adverse events from the included studies
showed that HM as an adjunct therapy has low incidence of
adverse effects. But no serious adverse effects were caused by
herbal medicines in COPD patients. The common adverse
effects are abdominal (“stomach”) discomfort, nausea and
vomiting, skin allergy, and pain. It should be pointed out
that only one-third of the studies (64 studies/176 studies) had
included adverse effect as outcomes. Moreover, studies have
shown that herb-drug interaction is a potential risk factor for
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the adverse events [56–58]. The safety of herbs or herb-drug
interaction in COPD treatment needs further investigation.
The quality of clinical trials has to be improved in
the future studies. In the present study, 15 studies (18
publications) were identified as high quality studies while
others were quasi-RCTs and RCTs with high risk bias. Ran-
domization is one of the major concerns in the clinical trials.
Most of the studies only stated that there is “randomization”
in them, even when there is a lack of the details about the
randomization methods. Descriptions of the methods may
minimize or avoid selection bias. Indeed, randomization in
some studies we reviewed has not been properly performed;
for instance, the patients have been allocated according
to the date or the odd and even sequence of admission.
Selection bias may also arise from inadequate allocation
concealments. In the 176 studies that have been reviewed,
only fifteen studies described concealments of allocation.
Central allocation or sequentially numbered, opaque, and
sealed envelopes are recommended in future studies.
Blinding is the critical method to minimize or avoid the
bias, which is absent in studies even in those studies with high
quality. Blinding to participants may avoid performance bias.
Placebo with similar odor, color, and taste to the intervention
should be applied in future studies. It is recommended that
there should be an outcome assessment to measure detection
bias when TCM practitioners are involved in diagnosing and
prescribing for patients.
Data incompetence is also a concern in clinical trials; for
instance, few studies reported the details on the dropout or
the followup of the study. Side effects or adverse effects should
be reported as the outcome of the trials.The clinical trials can
follow the international guideline for good clinical practice
that has been developed by the International Conference on
Harmonization Global Cooperation Group (http://www.ich
.org/products/guidelines/efficacy/article/efficacy-guidelines
.html). More importantly, it should be pointed out that not all
low quality studies are attributed to the low quality of clinical
trial design and conduct, but there is also inappropriate
or inadequate reporting. As most of the study information
comes from publications, the incomplete reporting of clinical
trials in articles increases unclear risk of bias. Consolidated
Standards of Reporting Trials (CONSORT) group has
developed the standard reporting guideline to alleviate the
problems arising from inadequate reporting of randomized
controlled trials [59].
5. Conclusion
Current evidence reveals that HM as an adjunct therapy
is uncertain to improve the pulmonary function but may
improve clinical symptoms and quality of life for COPD
patients. Studies with large scale and double-blind random-
ized controlled trials are required to confirm the role of HM
in the management of COPD.
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